Home > Insider Trading > Filing (0001209191-15-024608)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1347178	Vanda Pharmaceuticals Inc.	VNDA	Pharmaceutical Preparations (2834)	030491827

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1263499	W Richard Dugan	298 Beacon Circle Boalsburg PA 16827		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-03-09	10,574	$4.73	10,574	No	4	M	Direct
Common Stock	Disposition	2015-03-09	4,804	$10.69	5,770	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nonqualified Stock Option (Right to Buy)	Disposition	2015-03-09	10,574	$0.00	10,574	$4.73

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2015-12-29	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.66 to $10.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
Reflects the converted exercise price of each option share pursuant to the 1-for-3.309755 reverse stock split which occurred immediately following the effectiveness of the registration statement covering the issuer's initial public offering.
The Form 3 originally filed on April 12, 2006 inadvertently listed 10,571 shares of Common Stock instead of 10,574 shares of Common Stock.
Exercisable with respect to 660 shares immediately. Exercisable with respect to an additional 2.08333% of the aggregate option share total each month thereafter.